Abstract
Objective To assess the reporting discrepancy between officially confirmed COVID-19 death counts and unreported COVID-19-like illness (CLI) death counts.
Study Design The study is based on secondary time-series data.
Methods We used publicly available data to explore the differences between confirmed COVID-19 death counts and deaths with probable COVID-19 symptoms in Bangladesh between March 8, 2020, and July 18, 2020. Both tabular analysis and statistical tests were performed.
Results During the week ending May 9, 2020, the unreported CLI death count was higher than the confirmed COVID-19 death count; however, it was lower in the following weeks. On average, unreported CLI death counts were almost equal to the confirmed COVID-19 death counts during the study period. However, the reporting authority neither considers CLI deaths nor adjusts for potential seasonal influenza-like illness or other related deaths, which might produce incomplete and unreliable COVID-19 data and respective mortality rates.
Conclusions Deaths with probable COVID-19 symptoms needs to be included in provisional death counts in order to estimate an accurate COVID-19 mortality rate and to offer data-driven pandemic response strategies. An urgent initiative is needed to prepare a comprehensive guideline for reporting COVID-19 deaths.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was not sought as this study used publicly available data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Supplementary data and code of the article can be found at Harvard Dataverse (https://doi.org/10.7910/DVN/H9RHWN) upon request.
https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/H9RHWN
